GridAI Technologies Corp., formerly known as Entero Therapeutics, Inc., is a diversified technology and life sciences company operating through two principal areas: (i) energy orchestration and grid optimization software solutions through our subsidiary Grid AI Corp. and (ii) legacy biopharmaceutical development activities centered on Adrulipase for the treatment of exocrine pancreatic…
The business is unprofitable at the operating level (-19539.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$36K
Net Income (TTM)
-$9M
▲ +64.6% YoY
Op. Margin
-19539.98%
ROIC
-38.36%
▲ +499.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$7M
▲ +38.1% YoY
Op. Cash Flow (TTM)
-$7M
▲ +38.1% YoY
Net Debt
$2M
Cash & Equiv.
$386K
Continue Research